Skip to main content

Samuel Levy has served in leadership roles in multiple companies and in academic positions over the last 20 years. He has worked in diverse areas of genetics and genomics including human genome sequencing (Celera Genomics, J. Craig Venter Institute), clinical genomics and stem cell biology (Scripps Research Institute), oncology-based molecular diagnostics (Genomic Health) and single cell genomics for drug discovery (Quanticel Pharmaceutical acquired by Celgene). He co-founded Impact Genomics/Lexent Bio (acquired by Foundation Medicine) and was one of the early developers of epigenomics-derived liquid biopsy applications for molecular diagnostics at Bluestar Genomics.

Leave a Reply